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Low cardiac output is still the most frequent lethal complication after open-heart surgery for congenital heart disease. It is very often the result of low pressure and/or poor myocardial protection during the operation, so we feel that prevention is the most effective means of treatment for this complication.
Dopamine was introduced at the Hospital for Sick Children in July 1975, and has been used in about 80 cases of low cardiac output. Unfortunately, I cannot show you any hard data, so I give you our current ideas about the use of dopamine after open-heart surgery in babies and children.
We changed our policy in the treatment of low cardiac output in favour of dopamine because of the very specific cardiovascular actions of this drug, on myocardial performance and on peripheral vascular resistance. Dopamine has a positive inotropic effect, although this is less pronounced than with the other catecholamines such as adrenaline and isoprenaline. More important is that it has hardly any chronotropic effect when it is used in low doses. Another advantage is increased coronary perfusion caused by vasodilation in the coronary vascular bed. This increased myocardial performance together with increased myocardial blood flow results in an optimal supply/demand ratio, and this is in sharp contrast with adrenaline and isoprenaline. A third reason why dopamine is so attractive is the increased renal blood flow. This is again in contrast with adrenaline and isoprenaline, which do not produce a rise in renal plasma flow or sodium excretion to anything like the same extent.
However, we should also mention the disadvantages of dopamine. It has a weaker vasopressor effect than the other catacholamines, and its very specific action is very closely dose-related. If it is administered in high doses it loses all its advan- tages over the other catecholamines. We think that the disappointing results reported by some centres may be due to the fact that the dopamine was used at much too high a dose. This is especially true in babies and children where each dose has to be adjusted to the weight of the patient being treated. Our experience and the data in the literature are in accord over this. In low doses of 1-10 pg/kg per min, the drug has its optimal effect. At moderate doses of 10-20 jg/kg per min, it acts predominantly as an alpha-adrenergic receptor stimulating agent. This is certainly true in doses of 20 jig/kg: at this dose the patient will react with decreased urinary output and increased peripheral vasoconstriction.
To avoid over-dosage in small babies and children, we worked out a set of concentrations of dopamine in jig per microdrop corresponding to the weight of the child (Table 1) . For instance, a child of 4 kg will get a dilution of 25 mg in 100 ml dextrose water, so that each microdrop contains 4 jig. By this system, one microdrop per minute equals one microgram per kilogram body weight per minute. A child of 10 kg will get a solution of 50 mg of dopamine in 80 ml dextrose water. One microdrop then contains 10 jg, so that at one microdrop per minute the child gets one microgram of dopamine per kg per min. We usually start dopamine with 4 drops per minute, and increase this very gradually if we do not get the appropriate response. We often obtain a good response at a dose between 4 and 9 jg/kg per min.
The response in urinary output was striking in many cases, especially when dopamine was used in combination with diuretics.
However, in a great number of patients we used a combination of dopamine and low doses of other catecholamines. By low doses of catecholamine, I mean for instance 0.25-0.50 mg % isoprenaline added to the dopamine solution. This combination gives a very good vasopressor response without the deleterious effect of tachycardia so often encountered when isoprenaline is used alone. We use this combination in cases where we wish to enhance the vasopressor action of dopamine and where there is marked peripheral vasoconstriction. It had been our experience that dopamine in these cases did not result in increased urinary output because of an excessive alpha-adrenergic vasoconstriction.
In conclusion, we can state that, although we do not have the hard data, dopamine is currently our drug of first choice for the treatment of low cardiac output after open-heart surgery for congenital heart disease. However, we should keep in mind that dosages over 10 jg/kg per min should be avoided. We can avoid this overdosage by combining dopamine with very low doses of other catecholamines.
at SAGE Publications on June 21, 2016 jrs.sagepub.com Downloaded from Dopamine Hydrochloride DISCUSSION Dr A Miller (Chicago): I just want to make the speaker feel better and tell him that there are a few others of us here today who do not have a lot of hard data, and also to tell him that our experience in Chicago at Northwestern is essentially the same as his.
I am impressed that the surgeons are a little more prone to use the dopamine if there is any question of urine flow impairment, and they use it very readily and seem to use it very comfortably. They also like to mix it with other drugs, and in our hospital I find that they add isoproterenol and epinephrine.
Though I do not always know why, they insist that they are getting good results. They are able to get patients off cardiopulmonary bypass, and that seems to be the critical end result.
Dr Daenen: We think that with this combination it is very important to avoid high doses of dopamine, because we feel that all these patients are in myocardial oxygen debt when they come from the theatre, and therefore we try to keep this as low as possible by a combination of very low doses of dopamine plus other catecholamines. The choice of the catecholamine depends on the clinical condition of the patient.
Dr Thompson: I disagree wholeheartedly that there is any contraindication to using dopamine in doses greater than 10 or 20 jg/kg per min. If the patient is severely hypotensive and hypoperfused and has maximal heart filling pressures, there seems to me to be little alternative but to maintain perfusion with inotropic drugs unless mechanical assistance to the circulation is available. In such circumstances we have treated patients, including those with shock after myocardial infarction, with doses of up to 13000 jg/kg per min without producing serious tachyarrhythmias, and patients have left the hospital alive who required treatment for more than one hour with doses of dopamine of 200 to 300 jg/kg per min. I believe an appropriate interpretation of the results would be that prognosis is a function of the dosage of catecholamine required for hemodynamic effect. If the patient responds to dopamine in doses of 2 to 5 jig/kg per min, it would be absurd to push larger doses. If, however, the patient is refractory to doses of 20 jig/kg per min, I believe it would be equally absurd to regard this as an upper limit and then switch to equivalently higher doses of another catecholamine or to leave the patient severely hypotensive. Large doses of dopamine will increase arterial pressure in severely hypotensive patients, and we have not seen patients who achieved a greater desired pressor' effect from norepinephrine than from an appropriately higher dose of dopamine. In fact, we are now using dopamine during resuscitation with closed chest cardiac massage (doses of 10-20 mg/minute) rather than the previously standard noradrenaline (0.1-0.2 mg/minute). There are two instances in which adding another catecholamine to dopamine is important. First, in some patients on dopamine the heart rate decreases and, as Dr Goldberg demonstrated so well almost a decade ago, adding small doses of isoprenaline (0.5-2 jg/ min) will increase heart rate to levels appropriate in shock. Second, dopamine is not a bronchodilator and we add isoprenaline to dopamine when bronchodilation is desirable. I would like to make an additional point about the dose of dopamine. I do not think it logical, or pharmacologically correct, to express dose in the adult per unit of body weight. This is a pedantic rather than a precise exercise, for the appropriate dose in the adult may vary from 1 to 300 + jig/kg per min, but body weight hardly varies over this range, even between the chairman and me. Furthermore, dopamine does not distribute into body fat but into lean body mass. Therefore I believe it is just as useful to express dopamine doses in terms of mg/min, and this simplifies dilution of the drug in intravenous solutions and may minimize errors in calculation. In the children we have studied, the dosage range based on body weight is similar to the adult, and so body size may be of some value in adjusting doses in the nursery, but I think it causes only confusion rather than clarity on the adult wards.
Dr Daenen: I agree completely with you. Perhaps we were a little bit too cautious. But I cannot remember one patient who survived a dosage over 20 jig/kg weight.
Professor Groebecker (Frankfurt): I cannot see the pharmacological basis underlying your concept of a combination of both catecholamines, isoproterenol and dopamine. I would like to support Dr Goldberg's suggestion of combining dopamine and sodium nitroprusside. If you inject both dopamine and isoproterenol you will have a mixed effect of a beta receptor stimulating agentthat is isoproterenoland once again a beta receptor stimulating agentthat is dopamineand you try to overcome the alpha receptor action of dopamine by the beta receptor stimulation of isoproterenol. But then it is better to use a nonspecific drug like sodium nitroprusside in order to decrease the peripheral resistance. Do you not think so ?
Dr Daenen: Perhaps I was not very clear in my presentation, but we only use the combination of both drugs if the vasopressor effect of dopamine alone is not sufficient; then we add isoprenaline. Dr Thompson: The use of vasodilators is becoming more complex. There is a heated debate now between California and Boston-Bethesda regarding the relative values of nitroprusside and nitroglycerine after myocardial infarction. These agents may be quite different. Although I have used the combination of dopamine and nitroprusside, and found it quite useful in controlling independently the cardiac output, preload, and afterload, I prefer to use alpha-adrenergic antagonists, such as phentolamine, to block the vasoconstriction manifest at high doses of dopamine or in patients with high levels of endogenous catecholamines with profound vasoconstriction. Phentolamine has a clinical duration ofeffect of about 15 minutes in shock, and I have added it to the dopamine intravenous bottle so that the patient received 50 to 500 pg/ min. Phentolamine has also been effective alone in a few patients with profound vasoconstriction but no hypotension, and we have continued therapy for 3 days with no evidence of tolerance or toxicity.
There is one illogical way of using a vasodilator with dopamine. In some cases of profound vasoconstriction from the shock itself, from dopamine in high doses,or from adrenaline or noradrenaline, I have heard it said that the patient should receive isoprenaline to dilate the constricted vessels. Unfortunately, isoprenaline does not significantly dilate the renal, mesenteric, and other visceral arteriesit mostly dilates arteries to skeletal muscle, and thereby produces a 'shunt' of available cardiac output away from the essential viscera. In the presence of shock isoprenaline may increase the absolute amount of blood flowing to the kidneys, but the percentage of cardiac output directed there decreases as blood is 'shunted' to skeletal muscles. Now it may be perfectly appropriate to add isoprenaline to dopamine to increase heart rate or produce bronchodilation, or as a means of achieving an equivalent inotropic effect with smaller doses of each drug and thereby minimizing the peripheral vascular effects of both dopamine and isoprenaline. In such combinations, however, isoprenaline does not dilate the visceral vessels that are constricted in shock, but it may, by reducing the dose of dopamine required, result in equivalent additive heart force effect and lessen the dopamine alpha-adrenergic vasoconstriction.
Professor Goldberg (Chairman): I guess I am guilty of using all these drugs. Let me see if I can sort this out. My feelings are these: if you do not have enough cardiac output increase with dopamine because, as you push the dose up, there is increased vasoconstriction, then isoproterenol would be-a reasonable drug to add, being more direct. At the other extreme, if dopamine is causing too much vasoconstriction but is doing reasonably well with cardiac output, then one could add two things. One could use a nonspecific vasodilator such as nitroprusside, or one could use phentolamine. Both of these are hazardous because the perfusion pressure may drop. So I think that all this has to be considered very experimental at the present time.
I think that when you are treating a condition like this you must do what you think is best hemodynamically at the moment. We measure everything we can. All the drugs that I like to use are short acting, so that if something bad happens you can stop quickly and shift into another one. For that reason, at the moment I am tending to prefer nitroprusside, without much experience, to phentolamine. I think that this has to be worked out. There is just one possible advantage. I think that we shall have to have another meeting, about five years from now, to discuss which of these, if any, is more advisable.
Dr Daenen: In surgery after congenital heart disease we occasionally encounter patients with reactive pulmonary vascular resistance. Do you know what the effect of dopamine is on this reactive pulmonary vascular resistance?
Professor Goldberg: No, I do not know. Dopamine in very large doses can certainly increase pulmonary arterial resistance, just as any of the other constrictor drugs can. I have not had any experience with this, but Dr Harrison has a few papers in which he shows that, at least in patients with congestive heart failure, pulmonary arterial resistance does not increase in most of them. Occasional patients will show an increase.
Dr Daenen: Even with low doses? Professor Goldberg: I do not remember what dose level he used. But it is possible that a person who has a sensitized pulmonary arterial resistance could increase it.
Dr Thompson: Pulmonary vascular resistance is increased at high doses of dopamine, but the response to low doses (2 to 20 pg/kg per min) has been quite variable in our patients. Actually, in shock there is another important reason to monitor pulmonary arterial pressure, and that is to monitor the adequacy of ventilation. In patients who have the capability of increasing pulmonary arterial pressures, even momentary hypoxmmia or hypocarbia results in increased pulmonary arterial pressures that can be a very effective early warning system.
